Retained (old) foreign body following penetrating wound of orbit

H7_RETAINEDBODY

No definition available.

Endpoint definition

↥

Endpoint definition steps	FinnGen
Phenotype data	520210
1. Apply sex-specific rule None	520210
2. Check conditions None	520210
3. Check pre-conditions, main-only, mode, registry filters Registry filters: Hospital discharge: ICD-10 — H05.5 Hospital discharge: ICD-9 — 3766 Cause of death: ICD-10 — H05.5 Cause of death: ICD-9 — 3766 2 out of 7 registries used, show all original rules.	26
4. Check minimum number of events None	26
5. Include endpoints None	26
6. Filter based on genotype QC (FinnGen only)	26

Control definitions (FinnGen only)

Control exclude: H7_LIDLACRIMALORBIT

Extra metadata

Level in the ICD hierarchy: 4
First used in FinnGen datafreeze: DF2
Parent code in ICD-10: H05
Name in latin: Corpus alienum retentum [vetus] orbitae

NAME	H7_RETAINEDBODY
CONTROL_EXCLUDE	H7_LIDLACRIMALORBIT
CONTROL_PRECONDITIONS
CONTROL_CONDITIONS
SEX
INCLUDE
PRE_CONDITIONS
CONDITIONS
OUTPAT_ICD
OUTPAT_OPER
HD_MAINONLY
HD_ICD_10_ATC
HD_ICD_10	H055
HD_ICD_9	3766
HD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
HD_ICD_10_EXCL
HD_ICD_9_EXCL
HD_ICD_8_EXCL
COD_MAINONLY
COD_ICD_10	H055
COD_ICD_9	3766
COD_ICD_8	$!$	The FinnGen clinical team has checked and no code can be used for this rule.
COD_ICD_10_EXCL
COD_ICD_9_EXCL
COD_ICD_8_EXCL
OPER_NOM
OPER_HL
OPER_HP1
OPER_HP2
KELA_REIMB
KELA_REIMB_ICD
KELA_ATC_NEEDOTHER
KELA_ATC
KELA_VNRO_NEEDOTHER
KELA_VNRO
CANC_TOPO
CANC_TOPO_EXCL
CANC_MORPH
CANC_MORPH_EXCL
CANC_BEHAV

Similar endpoints

↥

List of similar endpoints to Retained (old) foreign body following penetrating wound of orbit based on the number of shared cases.

Similar with more cases:

Similar with less cases:

None

Case counts by codes

↥

FinnGen case counts by registry codes:

Upset plot

Full data table

Summary Statistics

↥

-FinRegistry-

Key figures

	All	Female	Male
Number of individuals
Whole population	217	55	161
Only index persons	203	51	152
Unadjusted period prevalence (%)
Whole population	0.00	0.00	0.00
Only index persons	0.00	0.00	0.01
Median age at first event (years)
Whole population	44.28	42.88	44.56
Only index persons	42.87	42.88	42.86

-FinnGen-

Key figures

	All	Female	Male
Number of individuals	26	7	19
Unadjusted period prevalence (%)	0.01	0.00	0.01
Median age at first event (years)	50.16	43.82	52.50

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

No data

-FinnGen-

Cumulative Incidence Function

Not a core endpoint, no data to show.

CodeWAS (R11)

↥

CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.

This is a new tool, please reach out using the contact form for feedback and improvement ideas.

First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log₁₀(p-value) ≥ 6.

No data available

LabWAS

↥

(ID) Name

N Cases

N Controls

-log₁₀(p)

cases

controls

cases

controls

unit

-log₁₀(p)

N cases

N controls

(3017143) Hepatitis C virus Ab [Presence] in Serum

4.77

2.62

1.4

1.8

—

(46235355) HIV 1 and 2 tests - Meaningful Use set

3.38

2.05

2.9

1.5

—

(3026008) Bacteria identified in Urine by Culture

2.94

1.45

1.8

1.9

—

(3002256) Pathology report gross observation

2.81

1.33

1.5

1.2

—

(3048689) Calprotectin [Mass/mass] in Stool

3.00

1.28

1.4

1.6

59.0

90.8

ug/g

—

(3019284) Hepatitis B virus surface Ag [Presence] in Serum

2.69

1.27

1.3

1.4

—

(3011397) Hemoglobin [Presence] in Urine by Test strip

2.43

1.26

6.4

3.0

—

(3015736) pH of Urine

2.37

1.23

5.2

2.9

—

(3002582) Erythrocytes [#/volume] in Urine

2.39

1.22

2.8

2.2

18.0

12.3

e6/l

—

(42870588) Differential panel, method unspecified - Blood

2.29

1.12

5.0

—

(3030467) Casts [#/volume] in Urine by Automated count

2.23

1.01

2.9

2.1

0.0

0.3

e6/l

—

(3019900) Cholesterol [Moles/volume] in Serum or Plasma

218

0.44

1.01

4.3

4.1

4.7

4.6

mmol/l

0.06

206

(3023602) Cholesterol in HDL [Moles/volume] in Serum or Plasma

218

0.44

1.01

4.2

4.0

1.4

mmol/l

0.03

206

(3048773) Triglyceride [Moles/volume] in Serum or Plasma --fasting

214

0.49

0.93

3.8

3.6

1.3

mmol/l

0.09

201

(40768804) Tissue Pathology biopsy report

2.03

0.86

2.6

2.1

—

(3044640) Blood type and Crossmatch panel - Blood

1.92

0.85

1.6

2.1

—

(3018095) Leukocytes [#/volume] in Urine

1.95

0.78

3.7

2.6

5.9

32.7

e6/l

—

(3033319) Streptococcus pyogenes Ag [Presence] in Throat

0.00

0.62

0.0

1.5

—

(3001308) Cholesterol in LDL [Moles/volume] in Serum or Plasma

222

0.57

0.59

4.3

4.4

2.9

2.8

mmol/l

0.29

208

(3013826) Glucose [Moles/volume] in Serum or Plasma

116

1.69

0.55

3.3

3.5

6.4

6.6

mmol/l

0.27

110

(3029287) Urinalysis microscopic panel [#/volume] - Urine by Automated count

1.70

0.51

4.6

2.5

—

(36304419) Bacteria [Presence] in Urine

1.69

0.50

3.3

2.1

—

(40758558) Short blood count panel - Blood

1.65

0.50

4.8

5.8

—

(43054914) Glucose tolerance 2 hours panel - Serum or Plasma

0.00

0.42

0.0

1.3

—

(3001079) Blood group antibody screen [Presence] in Serum or Plasma

1.56

0.41

2.8

4.2

—

(3044889) 12 lead EKG panel

145

1.50

0.39

3.3

3.4

—

(3013721) Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma

0.69

0.30

2.7

2.5

40.2

30.0

u/l

—

(3023368) Bacteria identified in Blood by Culture

1.39

0.25

11.4

4.8

—

(46236098) ABO and Rh group [Type] in Blood by Confirmatory method

1.27

0.23

1.6

2.1

—

(3001019) Free T4 and TSH panel - Serum or Plasma

0.00

0.22

0.0

2.6

—

(4034850)

0.00

0.22

0.0

7.3

—

(3004716) Salmonella sp identified in Stool by Organism specific culture

0.00

0.22

0.0

1.4

—

(3008898) HLA-B27 [Presence]

0.00

0.21

0.0

1.1

—

(3013512) EKG study

1.31

0.21

3.1

2.6

—

(4094501)

0.00

0.20

0.0

1.1

—

(3009542) Hematocrit [Volume Fraction] of Blood

195

1.40

0.20

13.6

10.7

42.7

41.6

0.42

167

(1761868) Lipid panel - Serum or Plasma

0.80

0.17

2.8

2.5

—

(706163) SARS-CoV-2 (COVID-19) RNA [Presence] in Respiratory system specimen by NAA with probe detection

146

0.78

0.16

3.5

2.9

—

(3001784) Prostate Specific Ag Free/Prostate specific Ag.total in Serum or Plasma

1.26

0.13

4.1

3.9

22.3

23.3

—

(3041096) Erythrocytes [Presence] in Urine by Automated

0.81

0.09

4.0

2.4

—

(40763086) Leukocyte esterase [Presence] in Urine by Automated test strip

0.84

0.08

8.6

2.9

—

(3037467) Urinalysis macro (dipstick) panel - Urine

130

1.17

0.06

5.2

2.9

—

(3013603) Prostate specific Ag [Mass/volume] in Serum or Plasma

116

0.91

0.01

4.5

3.9

2.7

1.9

ug/l

0.32

103

(3042596) Human coronavirus RNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.5

—

(3019250) Coagulation factor VIII activity actual/normal in Platelet poor plasma by Coagulation assay

0.00

0.0

2.2

—

168.8

—

(3050380) Cytology report of Cervical or vaginal smear or scraping Cyto stain

0.00

0.0

1.2

—

(3043109) Cytology report of Tissue fine needle aspirate Cyto stain

0.00

0.0

1.0

—

(3024172) Erythropoietin (EPO) [Units/volume] in Serum or Plasma

0.00

0.0

1.2

—

6.1

—

(3004588) Protein electrophoresis panel - Serum or Plasma

0.00

0.0

7.2

—

(3016650) Hepatitis A virus Ab [Presence] in Serum

0.00

0.0

1.2

—

(3011960) Natriuretic peptide B [Mass/volume] in Serum or Plasma

0.00

0.0

2.0

—

142.7

—

(3009595) Pneumocystis jiroveci DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.5

—

(3020565) Legionella pneumophila DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.5

—

(3030692) Respiratory virus DNA+RNA [Identifier] in Specimen by NAA with probe detection

0.00

0.0

1.5

—

(3003694) ABO and Rh group [Type] in Blood

1.03

0.00

1.0

1.2

—

(40765161) Human bocavirus DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.5

—

(3049804) Myeloperoxidase IgG Ab [Units/volume] in Serum

0.00

0.0

1.0

—

(40768793) Breast Pathology biopsy report

0.00

0.0

1.0

—

(21494670) JAK2 gene exon 14 targeted mutation analysis in Blood or Tissue by Molecular genetics method

0.00

0.0

1.0

—

(3051552) Clostridioides difficile toxin genes [Presence] in Stool by NAA with probe detection

0.00

0.0

1.8

—

(3008909) Norovirus RNA [Presence] in Stool by NAA with probe detection

0.00

0.0

1.0

—

(3025018) Bordetella pertussis Ab [Titer] in Serum

0.00

0.0

1.0

—

(44790048)

0.00

0.0

2.2

—

(3040853) Adenovirus DNA [Identifier] in Specimen by NAA with probe detection

0.00

0.0

1.8

—

(44806118)

0.00

0.0

2.2

—

(3016407) Fibrinogen [Mass/volume] in Platelet poor plasma by Coagulation assay

0.00

0.0

2.1

—

3.3

—

(44790049)

0.00

0.0

2.2

—

(3005702) Mycobacterium sp identified in Specimen by Organism specific culture

0.00

0.0

1.1

—

(40762366) Oxygen capacity [Volume Fraction] in Arterial blood

0.00

0.0

8.0

—

(3012477) Bordetella pertussis DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.7

—

(3024891) Influenza virus A+B Ag [Presence] in Specimen

0.00

0.0

1.4

—

(3015816) F5 gene p.Arg506Gln [Presence] in Blood or Tissue by Molecular genetics method

0.00

0.0

1.0

—

(44790047)

0.00

0.0

2.2

—

(3002482) Mycoplasma pneumoniae DNA [Presence] in Specimen by NAA with probe detection

0.00

0.0

1.7

—

(3003191) Choriogonadotropin (pregnancy test) [Presence] in Serum or Plasma

0.00

0.0

1.1

—

(3004529) Oxygen [Partial pressure] adjusted to patient's actual temperature in Venous blood

0.00

0.0

3.4

—

40.5

—

(3024403) Complement+Immunoglobulin [Units/volume] in Red Blood Cells

0.00

0.0

1.4

—

(40768443) Skin Pathology biopsy report

0.00

0.0

1.0

—

(3030366) Cystatin C [Mass/volume] in Serum or Plasma

0.00

0.0

2.0

—

1.5

—

(3027273) Bicarbonate [Moles/volume] in Venous blood

0.00

-0.00

0.0

8.1

—

22.4

—

(3000515) Antithrombin actual/normal in Platelet poor plasma by Chromogenic method

0.00

-0.00

0.0

1.6

—

93.8

—

(3042194) Human metapneumovirus RNA [Presence] in Specimen by NAA with probe detection

0.00

-0.00

0.0

1.9

—

(3025941) Bacteria identified in Stool by Culture

0.00

-0.00

0.0

1.1

—

(3031478) Chlamydophila pneumoniae DNA [Presence] in Specimen by NAA with probe detection

0.00

-0.00

0.0

1.6

—

Mortality – FinRegistry

↥

Association

Association between endpoint H7_RETAINEDBODY and mortality.

Females

No data

Males

No data

Mortality risk

Mortality risk for people of age

years, who have H7_RETAINEDBODY.

N-year risk	Females	Males
1	No data	No data
5	No data	No data
10	No data	No data
15	No data	No data
20	No data	No data

Relationships between endpoints

↥

Index endpoint: H7_RETAINEDBODY – Retained (old) foreign body following penetrating wound of orbit

GWS hits: -

Endpoint

Case Overlap

Survival Analysis

Genetic Correlations

Genetic Signals

N (Jaccard index)

HR [CI]

rg [CI]

Hits

Coloc Hits

FinRegistry

FinnGen

FinRegistry

FinnGen

Loading data

Retained (old) foreign body following penetrating wound of orbit

Endpoint definition

Endpoint definition steps

FinnGen

Phenotype data

1. Apply sex-specific rule

2. Check conditions

3. Check pre-conditions, main-only, mode, registry filters

4. Check minimum number of events

5. Include endpoints

6. Filter based on genotype QC (FinnGen only)

Similar endpoints

Case counts by codes

Summary Statistics

-FinRegistry-

Key figures

-FinnGen-

Key figures

-FinRegistry-

Age distribution of first events

-FinnGen-

Age distribution of first events

-FinRegistry-

Year distribution of first events

-FinnGen-

Year distribution of first events

-FinRegistry-

Cumulative Incidence Function

-FinnGen-

Cumulative Incidence Function

CodeWAS (R11)

LabWAS

Mortality – FinRegistry

Association

Females

Males

Mortality risk

Relationships between endpoints